Cystatin C levels in left ventricular hypertrophy and chronic kidney disease secondary to arterial hypertension
- VernacularTitle:Артерийн гипертензиэс үүдэлтэй зүрхний зүүн ховдлын томрол, бөөрний архаг дутагдлын үе дэх цистатин С-ийн түвшинг судалсан нь
- Author:
Khongorzul Ts
1
;
Otgonjargal Ch
1
;
Munkh-Erdene U
1
;
Odgerel Ch
1
;
Oyun-Erdene R
1
;
Nandin-Erdene M
1
;
Buyankhuu T
1
;
Munkhtsetseg J
1
;
Tulgaa S
1
Author Information
1. Department of Biochemistry, School of Biomedicine, MNUMS
- Publication Type:Journal Article
- From:
Diagnosis
2025;113(2):63-68
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Identifying reliable biomarkers for early detection, risk stratification, and prognosis of CVD in the context of CKD is, therefore, of critical importance. Cystatin C has emerged as a potential biomarker capable of reflecting both cardiac injury and renal impairment, particularly in patients with arterial hypertension. This study aimed to evaluate the association between serum cystatin C levels, left ventricular hypertrophy, and chronic kidney disease in individuals with hypertension.
Objective:To assess serum cystatin C concentrations in patients with left ventricular hypertrophy and chronic kidney disease secondary to arterial hypertension.
Materials and Methods:A case-control analytical study was conducted, enrolling 44 patients aged 45 years or older with both left ventricular hypertrophy and chronic kidney disease due to arterial hypertension alongside a control group of apparently healthy individuals. Serum cystatin C levels were measured using immunoturbidimetric assay. Statistical analysis was performed using SPSS version 25.0. Group comparisons were made using independent-sample t-tests, while multivariate regression and receiver operating characteristic (ROC) analyses were employed to explore associations and the predictive value of cystatin C.
Results:The mean serum cystatin C concentration in the case group was 1.6±0.1 mg/L, significantly higher than in the control group (0.88±0.03 mg/L, p<0.05). Similarly, the estimated glomerular filtration rate (eGFR) was markedly reduced in the case group (44.88±6.8 mL/min/1.73 m²) compared to the controls (92.88±3.4 mL/ min/1.73 m², p<0.05). In the case group, a statistically significant inverse correlation was observed between serum cystatin C levels and glomerular filtration rate (GFR), with a regression coefficient of β=−0.028 (p<0.006).
Conclusion:The elevated serum cystatin C levels (1.6±0.1 mg/L) and decreased eGFR (38.99±12.7 mL/min/1.73 m²) observed in the case group suggest that cystatin C may serve as a potential biomarker for the early diagnosis of left ventricular hypertrophy due to arterial hypertension and chronic kidney disease, as well as for predicting related complications.
- Full text:2025111416185896534Diagnosis-2025-113(2)-63-68.pdf
